# A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

> **NCT00539968** · PHASE1,PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 5 (actual)

## Conditions studied

- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Gastric Cancer

## Interventions

- **DRUG:** Docetaxel plus lonafarnib

## Key facts

- **NCT ID:** NCT00539968
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2015-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539968, "A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00539968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*